Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial

医学 吉西他滨 卡铂 内科学 化疗 转移性乳腺癌 乳腺癌 肿瘤科 三阴性乳腺癌 胃肠病学 癌症 外科 顺铂
作者
Antoinette R. Tan,Gail S. Wright,Anu Thummala,Michael A. Danso,Lazar Popović,Timothy Pluard,Hyo S. Han,Željko Vojnović,Nikola Vasev,Ling Ma,Donald Richards,Sharon Wilks,Dušan Milenković,Yang Zhao,Joyce Antal,Shannon R. Morris,Joyce O’Shaughnessy
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:20 (11): 1587-1601 被引量:105
标识
DOI:10.1016/s1470-2045(19)30616-3
摘要

Summary

Background

Trilaciclib is an intravenous cell-cycle inhibitor that transiently maintains immune cells and haemopoietic stem and progenitor cells in G1 arrest. By protecting the immune cells and bone marrow from chemotherapy-induced damage, trilaciclib has the potential to optimise antitumour activity while minimising myelotoxicity. We report safety and activity data for trilaciclib plus gemcitabine and carboplatin chemotherapy in patients with metastatic triple-negative breast cancer.

Methods

In this randomised, open-label, multicentre, phase 2 study, adult patients (aged ≥18 years) with evaluable, biopsy-confirmed, locally recurrent or metastatic triple-negative breast cancer who had no more than two previous lines of chemotherapy were recruited from 26 sites in the USA, three in Serbia, two in North Macedonia, one in Croatia, and one in Bulgaria; sites were academic and community hospitals. Availability of diagnostic samples of tumour tissue confirming triple-negative breast cancer was a prerequisite for enrolment. Eligible patients were randomly assigned (1:1:1) by an interactive web-response system, stratified by number of previous lines of systemic therapy and the presence of liver metastases, to receive intravenous gemcitabine 1000 mg/m2 and intravenous carboplatin (area under the concentration-time curve 2 μg × h/mL) on days 1 and 8 (group 1), gemcitabine and carboplatin plus intravenous trilaciclib 240 mg/m2 on days 1 and 8 (group 2), or gemcitabine and carboplatin on days 2 and 9 plus trilaciclib on days 1, 2, 8, and 9 (group 3) of 21-day cycles. Patients continued treatment until disease progression, unacceptable toxicity, withdrawal of consent, or discontinuation by the investigator. The primary objective was to assess the safety and tolerability of combining trilaciclib with gemcitabine and carboplatin chemotherapy. The primary endpoints were duration of severe neutropenia during cycle 1 and the occurrence of severe neutropenia during the treatment period. Overall survival was included as a key secondary endpoint. Analyses were in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of study treatment. This study is registered with EudraCT, 2016-004466-26, and ClinicalTrials.gov, NCT02978716, and is ongoing but closed to accrual.

Findings

Between Feb 7, 2017, and May 15, 2018, 142 patients were assessed for eligibility and 102 were randomly assigned to group 1 (n=34), group 2 (n=33), or group 3 (n=35). Of all patients, 38 (37%) had received one or two lines of previous chemotherapy in the metastatic setting. Median follow-up was 8·4 months (IQR 3·8–13·6) for group 1, 12·7 months (5·5–17·4) for group 2, and 12·9 months (6·7–16·8) for group 3. Data cutoff for myelosuppression endpoints was July 30, 2018, and for antitumour activity endpoints was May 17, 2019. During cycle 1, mean duration of severe neutropenia was 0·8 day (SD 2·4) in group 1, 1·5 days (3·5) in group 2, and 1·0 day (2·6) in group 3 (group 3 vs group 1 one-sided adjusted p=0·70). Severe neutropenia occurred in nine (26%) of 34 patients in group 1, 12 (36%) of 33 patients in group 2, and eight (23%) of 35 patients in group 3 (p=0·70). Overall survival was 12·6 months (IQR 5·8–15·6) in group 1, 20·1 months (9·4–not reached) in group 2, and 17·8 months (8·8–not reached) in group 3 (group 3 vs group 1 two-sided p=0·0023). The most common treatment-emergent adverse events were anaemia (22 [73%] of 34), neutropenia (21 [70%]), and thrombocytopenia (18 [60%]) in group 1; neutropenia (27 [82%] of 33), thrombocytopenia (18 [55%]) and anaemia (17 [52%]) in group 2; and neutropenia (23 [66%] of 35), thrombocytopenia (22 [63%]), and nausea (17 [49%]) in group 3. There were no treatment-related deaths.

Interpretation

No significant differences were observed in myelosuppression endpoints with trilaciclib plus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer; however, the regimen was generally well tolerated and overall survival results were encouraging. Further studies of trilaciclib in this setting are warranted.

Funding

G1 Therapeutics.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
Cao完成签到 ,获得积分10
刚刚
ENG完成签到,获得积分10
2秒前
alick完成签到,获得积分10
4秒前
刘刘完成签到,获得积分10
5秒前
Tom完成签到,获得积分10
6秒前
Villanellel发布了新的文献求助10
7秒前
程艳完成签到 ,获得积分10
8秒前
MINGHUI完成签到,获得积分10
9秒前
9秒前
子车半烟完成签到,获得积分10
9秒前
11秒前
淳于安筠完成签到,获得积分10
11秒前
雨晴完成签到,获得积分10
14秒前
jbq发布了新的文献求助10
14秒前
joshar完成签到,获得积分10
14秒前
15秒前
量子星尘发布了新的文献求助10
17秒前
blueblue完成签到,获得积分10
19秒前
落后秋烟完成签到,获得积分10
21秒前
大橙子发布了新的文献求助10
22秒前
LMY完成签到 ,获得积分10
22秒前
Betty完成签到 ,获得积分10
22秒前
NexusExplorer应助jbq采纳,获得10
23秒前
渔渔完成签到 ,获得积分10
23秒前
24秒前
Tangyartie完成签到 ,获得积分10
24秒前
skbkbe完成签到 ,获得积分10
25秒前
陈俊雷完成签到 ,获得积分0
26秒前
阿苗完成签到,获得积分10
27秒前
神勇的天问完成签到 ,获得积分10
28秒前
28秒前
advance完成签到,获得积分10
28秒前
李cc发布了新的文献求助10
29秒前
蒋念寒发布了新的文献求助10
30秒前
Sindy完成签到,获得积分10
30秒前
彭于晏应助HH采纳,获得30
32秒前
32秒前
朴实的小萱完成签到 ,获得积分10
33秒前
科研通AI5应助哭泣笑柳采纳,获得10
33秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038184
求助须知:如何正确求助?哪些是违规求助? 3575908
关于积分的说明 11373872
捐赠科研通 3305715
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022